RCKT Stock Dives Despite Gene Therapy Approval — Wall Street Dismisses Sell-Off
Rocket Pharmaceuticals (RCKT) shares fell 22% despite FDA approval of its gene therapy Kresladi for a rare pediatric disorder. The company received a Rare Pediatric Disease Priority Review Voucher. Analysts from Wedbush and LifeSci Capital maintained 'Outperform' ratings, citing the milestone and potential financial benefits. RCKT stock has dropped 53% in the past year.
How this was made
The 30-second read
Why it matters
The approval is a material regulatory event, yet the stock fell sharply, creating a potential short‑term trading opportunity.
Market read
Regulatory approval for a rare‑disease therapy is a primary catalyst; the unexpected price drop offers a contrarian entry point.
What to watch
Analyst coverage remains positive and the therapy addresses an ultra‑rare disease with little competition.
Background
Rocket Pharmaceuticals announced FDA approval of its Kresladi gene therapy for severe leukocyte adhesion deficiency‑I and received a Rare Pediatric Disease Priority Review Voucher.
Ticker impact
FDA approved Rocket's gene therapy Kresladi and granted a Rare Pediatric Disease PRV, yet the stock fell 22% on Friday.
Potential rebound of 5‑10% over the next few days if investors reassess the PRV value.
Approval is material, but the market overreacted; analysts maintain Outperform ratings and see non‑dilutive capital upside.
Market effects
Highlights continued volatility in rare‑disease biotech sector despite regulatory wins.
US biotech indices may see modest pullback as investors digest the sell‑off.
Limited to investors in US‑listed gene‑therapy companies.
Counterpoint
The drop may be an overreaction; the PRV and potential cash infusion could drive upside.
Key entities
- companyRocket Pharmaceuticals Inc.
US‑listed biotech (NASDAQ: RCKT) developing gene therapies.
- regulatorFDA
U.S. Food and Drug Administration granting approval and PRV.
